Cardiovascular disease

Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates at 2021 R&D Day

Thursday, October 21, 2021 - 1:30pm

21 October 2021, LONDON and NEW YORK -- Silence Therapeutics plc (AIM:SLN and Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, announces it is hosting its R&D Day in New York City today.

Key Points: 
  • Silence's proprietary mRNAi GOLD platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity.
  • Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements.
  • Silence will also provide an update on its growing discovery pipeline and plans to deliver 2-3 INDs per year from 2023.
  • Silence remains on-track to deliver 2-3 INDs per year from 2023 through both its proprietary and partnered mRNAi GOLD platform programs.

Life Sciences Operations Outsourcing Is Expected to Grow 9-11% Through 2022 --Everest Group

Thursday, October 21, 2021 - 1:00pm

The rising demand for technological support is one of many trends compelling firms in the life sciences industry to rethink their strategy and operations.

Key Points: 
  • The rising demand for technological support is one of many trends compelling firms in the life sciences industry to rethink their strategy and operations.
  • The rise in spending will be partly utilized to purchase medication and MedTech devices, thereby boosting the life sciences market in the region.
  • Additionally, life sciences firms are increasingly outsourcing their R&D activities in a bid to reduce cost.
  • These trends have generated rapid traction in the life sciences outsourcing market as service providers accelerate their efforts to assist enterprises in augmenting their operations by delivering services and solutions across the life sciences operations value chain.

Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

Thursday, October 21, 2021 - 11:30am

A live webcast will be available in the investor section of the company's website at www.vervetx.com .

Key Points: 
  • A live webcast will be available in the investor section of the company's website at www.vervetx.com .
  • The webcast will be archived for 60 days following the presentation.
  • Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines.
  • VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

Wednesday, October 20, 2021 - 12:05pm

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarins senior management team to discuss the Company's third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m.

Key Points: 
  • DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarins senior management team to discuss the Company's third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m.
  • The conference call will follow the anticipated release of the company's financial results earlier that day.
  • Conference Call and Webcast Information:
    Amarin will host a conference call November 3, 2021, at 7:30 a.m.
  • A replay of the call will be made available for a period of two weeks following the conference call.

NFL Alumni Performance Labs Forms Exclusive Partnership with to Deliver Best-in-Class Predictive Vital Sign Analytics

Thursday, October 21, 2021 - 2:46pm

With various advanced technologies such as remote photoplethysmography (rPPG) and AI recognised for its data accuracy, Nervotec will co-develop sports performance insights for athletes with NFLA from remotevital signs data analytics at NFL Alumni Performance Labs .

Key Points: 
  • With various advanced technologies such as remote photoplethysmography (rPPG) and AI recognised for its data accuracy, Nervotec will co-develop sports performance insights for athletes with NFLA from remotevital signs data analytics at NFL Alumni Performance Labs .
  • NFL Alumni Performance Labs is a first-of-its-kind full-service concierge wellness service with in-person and virtual service options designed for its alumni.
  • The partnership with Nervotec would provide remote health monitoring and predictive analytics to help NFL Alumni Performance Labs in delivering advanced human performance and integrated medicine services across its high-tech gyms in the US.
  • Dr Chuck Morris, CEO of NFL Alumni Performance Labs, said, "The inclusion of predictive vital sign analytics will be key in delivering our state-of-the-art sports performance facilities all over the US.

Action for bone health is needed now more than ever, urges IOF

Wednesday, October 20, 2021 - 6:30am

Worldwide, osteoporosis-related fractures affect up to one in three women and one in five men aged 50 years and over.

Key Points: 
  • Worldwide, osteoporosis-related fractures affect up to one in three women and one in five men aged 50 years and over.
  • IOF President Professor Cyrus Cooper noted:
    "The pandemic's continuing toll on bone health and the timely delivery of osteoporosis assessment and care is of global concern.
  • Given this backdrop, it is more important than ever to be proactive on behalf of bone health.
  • Such life-changing injuries can be prevented with life-long attention to bone health, and early diagnosis and appropriate treatment for those at risk."

Action for bone health is needed now more than ever, urges IOF

Wednesday, October 20, 2021 - 6:30am

NYON, Switzerland, Oct. 20, 2021 /PRNewswire/ -- A backlog in osteoporosis assessments, treatment delays, and sedentary indoor lifestyles: these are just several ways in which the Covid-19 pandemic has impacted bone health and disrupted global osteoporosis care.

Key Points: 
  • Worldwide, osteoporosis-related fractures affect up to one in three women and one in five men aged 50 years and over.
  • IOF President Professor Cyrus Cooper noted:
    "The pandemic's continuing toll on bone health and the timely delivery of osteoporosis assessment and care is of global concern.
  • Given this backdrop, it is more important than ever to be proactive on behalf of bone health.
  • Such life-changing injuries can be prevented with life-long attention to bone health, and early diagnosis and appropriate treatment for those at risk."

Cardisio GmbH Completes €3.5 Million Investment

Tuesday, October 19, 2021 - 4:30pm

FRANKFURT, Germany, Oct. 19, 2021 /PRNewswire/ -- Cardisio GmbH, developers of the world's first non-invasive, highly accurate screening method for heart diseases, today announced completion of its largest investment round to date.

Key Points: 
  • FRANKFURT, Germany, Oct. 19, 2021 /PRNewswire/ -- Cardisio GmbH, developers of the world's first non-invasive, highly accurate screening method for heart diseases, today announced completion of its largest investment round to date.
  • A group of private investors has infused 3.5 million in Cardisio.
  • Cardisio GmbH is headquartered in Frankfurt, Germany, and has offices in Berlin and San Francisco.
  • Cardisio is a registered trademark of Cardisio GmbH.

Genetesis Announces Two Abstracts Selected for Presentations at Upcoming Scientific Meetings

Tuesday, October 19, 2021 - 3:15pm

Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the companys lead product, CardioFlux was selected for abstract presentations at this years American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November.

Key Points: 
  • Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the companys lead product, CardioFlux was selected for abstract presentations at this years American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November.
  • These presentations will discuss the utility and improvements to standard of care when using CardioFlux as a diagnostic imaging solution to detect myocardial ischemia and diagnose coronary artery disease.
  • The CardioFlux Magnetocardiograph has been designated a FDA Breakthrough Device for its potential benefits in improving and optimizing care in the triage process.
  • Genetesis was founded in 2013 and is based in Mason, Ohio.

Governmental Public Health Agencies to Partner with National Nonprofits to Build Culture of Health

Tuesday, October 19, 2021 - 3:03pm

These challenges range from a disinvestment in public health to a workforce deeply impacted by the global pandemic to the public health crisis of racism and oppression.

Key Points: 
  • These challenges range from a disinvestment in public health to a workforce deeply impacted by the global pandemic to the public health crisis of racism and oppression.
  • "Public Health at its core is governmental," according to Rene Branch Canady, PhD, MPA, chief executive officer, MPHI "This initiative leverages the capacity of public health partners to advance the vital and shared agenda of state public health leaders.
  • ASTHO members, the chief health officials of these jurisdictions, are dedicated to formulating and influencing sound public health policy and to ensuring excellence in public health practice.
  • About MPHI: MPHI is a Michigan-based, non-profit public health institute leading public health efforts across the country.